Krishna Kant Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Krishna Kant Sharma has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Shruti Ahlawat
Laboratory of Enzymology and Recombinant DNA Technology, Department of Microbiology, Maharshi Dayanand University, Rohtak, India
12 shared publicationsAkshay Shankar
Maharshi Dayanand University
8 shared publicationsAsha Yadav
Laboratory of Enzymology and Gut Microbiology, Department of Microbiology, Maharshi Dayanand University
8 shared publicationsDeepti Singh
Laboratory of Enzymology and Gut Microbiology, Department of Microbiology, Maharshi Dayanand University, Rohtak 124001, Haryana, India
8 shared publicationsPratik Balwant Shinde
Laboratory of Enzymology and Gut Microbiology, Department of Microbiology, Maharshi Dayanand University
6 shared publicationsSonu Saini
Maharshi Dayanand University
6 shared publications
Latest Publications
- 30 May 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
Probiotics and Postbiotics in Life-Style Disease Management: A Comprehensive Review on the Technologies in the Era of Omics and Artificial Intelligence
Both conventional and next-generation probiotics play a crucial role in maintaining host homeostasis. They modulate insulin sensitivity, immune-regulation, lipid metabolism, and trimethylamine synthesis. In recent years, probiotics have emerged as an effective and safe alternative to antibiotics for treating chronic life-style disorders via gut-organ-axis. Accounting for that, they contributed a market size of 71.2 billion USD in the year 2024. However, effective consortia that can completely address all the symptoms of a particular disease are still lacking. Further, natural probiotics also face the issues of low survival rate and transfer of antibiotic resistance genes. Thus, postbiotics, which act as the ultimate mediators of gut-organ-axis have gained recognition over probiotics. They bind with multiple receptors present in host organs and modulate their functioning. This suggests the multilayer-multichannel axis between postbiotics and host vital organs. However, postbiotics cannot colonize the gut, and dosage and time also need optimization. Hence, engineered probiotics are being developed for efficient self-regulatory release of postbiotics at the target site. There are a few reviews on the topic of probiotics and lifestyle diseases; however, there is an urgent need for a critical appraisal synchronous with the fast-evolving technology, including omics and artificial intelligence. Thus, our article discusses advancements in technology to address the shortcomings of probiotics and postbiotics using genome editing, machine learning, and functional genomics techniques. It also covers the detailed application of artificial intelligence in probiotic consortia formulation, disease diagnosis, novel postbiotics detection, genetically engineered probiotics, and personalized therapies.
- 30 May 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
Probiotics and Postbiotics in Life-Style Disease Management: A Comprehensive Review on the Technologies in the Era of Omics and Artificial Intelligence
Both conventional and next-generation probiotics play a crucial role in maintaining host homeostasis. They modulate insulin sensitivity, immune-regulation, lipid metabolism, and trimethylamine synthesis. In recent years, probiotics have emerged as an effective and safe alternative to antibiotics for treating chronic life-style disorders via gut-organ-axis. Accounting for that, they contributed a market size of 71.2 billion USD in the year 2024. However, effective consortia that can completely address all the symptoms of a particular disease are still lacking. Further, natural probiotics also face the issues of low survival rate and transfer of antibiotic resistance genes. Thus, postbiotics, which act as the ultimate mediators of gut-organ-axis have gained recognition over probiotics. They bind with multiple receptors present in host organs and modulate their functioning. This suggests the multilayer-multichannel axis between postbiotics and host vital organs. However, postbiotics cannot colonize the gut, and dosage and time also need optimization. Hence, engineered probiotics are being developed for efficient self-regulatory release of postbiotics at the target site. There are a few reviews on the topic of probiotics and lifestyle diseases; however, there is an urgent need for a critical appraisal synchronous with the fast-evolving technology, including omics and artificial intelligence. Thus, our article discusses advancements in technology to address the shortcomings of probiotics and postbiotics using genome editing, machine learning, and functional genomics techniques. It also covers the detailed application of artificial intelligence in probiotic consortia formulation, disease diagnosis, novel postbiotics detection, genetically engineered probiotics, and personalized therapies.
- 1 May 2025
- Published by Oxford University Press (OUP) in Letters in Applied Microbiology
- Vol. 78 (5)
Xenobiotics mediated modulation of gut microbiota and its role in lifestyle diseases: a critical appraisal on exposomics
Gastrointestinal tract of humans provides a niche to thousands of microbes, referred as gut microbiota (GM). GM establishes an intricate relationship with other organs via gut–organ axis, and modulates host health. The structure and functioning of these gut microbes can be influenced by the type of external exposome an individual experiences. Depending upon GM perturbations and host genotype, this can result in variable health implications. On the other hand, the huge arsenal of enzymes possessed by GM can chemically alter the xenobiotic structure. Its consequences can be numerous, including formation of harmful metabolites that cause organ damage, reversal of host detoxification pathways, or favourable health effects. Additionally, GM-mediated bio-transformation of pharmaceuticals can alter their pharmacokinetics and pharmacodynamics, potentially yielding variable drug responses, resulting into prolonged or ineffective treatments. To address this bi-facial relationship and the pivotal role of GM, this review incorporates recent in vitro, in vivo, and multiomics studies. It also suggests the need of machine learning approaches to decode the complex host–microbiota–xenobiotics interactions. These knowledge will aid in comprehending recent rise in chronic lifestyle-diseases which poses a huge burden on the health sector, and can also be a learning curve in making formulations and therapies for personalized treatment.
- 1 May 2025
- Published by Oxford University Press (OUP) in Letters in Applied Microbiology
- Vol. 78 (5)
Xenobiotics mediated modulation of gut microbiota and its role in lifestyle diseases: a critical appraisal on exposomics
Gastrointestinal tract of humans provides a niche to thousands of microbes, referred as gut microbiota (GM). GM establishes an intricate relationship with other organs via gut–organ axis, and modulates host health. The structure and functioning of these gut microbes can be influenced by the type of external exposome an individual experiences. Depending upon GM perturbations and host genotype, this can result in variable health implications. On the other hand, the huge arsenal of enzymes possessed by GM can chemically alter the xenobiotic structure. Its consequences can be numerous, including formation of harmful metabolites that cause organ damage, reversal of host detoxification pathways, or favourable health effects. Additionally, GM-mediated bio-transformation of pharmaceuticals can alter their pharmacokinetics and pharmacodynamics, potentially yielding variable drug responses, resulting into prolonged or ineffective treatments. To address this bi-facial relationship and the pivotal role of GM, this review incorporates recent in vitro, in vivo, and multiomics studies. It also suggests the need of machine learning approaches to decode the complex host–microbiota–xenobiotics interactions. These knowledge will aid in comprehending recent rise in chronic lifestyle-diseases which poses a huge burden on the health sector, and can also be a learning curve in making formulations and therapies for personalized treatment.
- 25 April 2025
- Published by Springer Nature
- p. 237-252
Lignocellulosic Enzymes from Termite Gut for the Degradation of Plant Biomass
- 25 April 2025
- Published by Springer Nature
- p. 237-252
Lignocellulosic Enzymes from Termite Gut for the Degradation of Plant Biomass
- Open Access
- 12 December 2024
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 13 (12) , e0071924
Draft genome sequences of multi-drug-resistant Escherichia coli strains isolated from ulcerative colitis patients
The whole-genome sequences of four multi-drug-resistant Escherichia coli strains, namely, DAK02, DAK03, DAK05, and DAK10, are reported here. The E. coli strains were isolated from fecal samples of ulcerative colitis patients from Northern India. The size of the draft genome sequence ranged from 4,809 to 5,000 kb.
- 12 December 2024
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 13 (12) , e0071924
Open AccessDraft genome sequences of multi-drug-resistant Escherichia coli strains isolated from ulcerative colitis patients
The whole-genome sequences of four multi-drug-resistant Escherichia coli strains, namely, DAK02, DAK03, DAK05, and DAK10, are reported here. The E. coli strains were isolated from fecal samples of ulcerative colitis patients from Northern India. The size of the draft genome sequence ranged from 4,809 to 5,000 kb.
- 16 October 2024
- Published by Springer Nature
- p. 235-251
Lignocellulosic Biomass Based Biorefinery Employing Fungus and its Enzymes: Indian Perspective and Global Trend
- 16 October 2024
- Published by Springer Nature
- p. 235-251
Lignocellulosic Biomass Based Biorefinery Employing Fungus and its Enzymes: Indian Perspective and Global Trend
- 29 July 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (4) , 107289
Gut colonization with antibiotic-resistant Escherichia coli pathobionts leads to disease severity in ulcerative colitis
- 29 July 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (4) , 107289
Gut colonization with antibiotic-resistant Escherichia coli pathobionts leads to disease severity in ulcerative colitis
- 10 July 2024
- Published by Springer Nature in Biotechnology Letters
- Vol. 46 (5) , 1-20
Proteome profiling, biochemical and histological analysis of diclofenac-induced liver toxicity in Yersinia enterocolitica and Lactobacillus fermentum fed rat model: a comparative analysis
Diclofenac is a hepatotoxic non-steroidal anti-inflammatory drug (NSAID) that affects liver histology and its protein expression levels. Here, we studied the effect of diclofenac on rat liver when co-administrated with either Yersinia enterocolitica strain 8081 serotype O:8 biovar 1B (D*Y) or Lactobacillus fermentum strain 9338 (D*L). Spectroscopic analysis of stool samples showed biotransformation of diclofenac. When compared with each other, D*Y rats lack peaks at 1709 and 1198 cm−1, while D*L rats lack peaks at 1411 cm−1. However, when compared to control, both groups lack peaks at 1379 and 1170 cm−1. Assessment of serum biomarkers of hepatotoxicity indicated significantly altered activities of AST (D*Y: 185.65 ± 8.575 vs Control: 61.9 ± 2.607, D*L: 247.5 ± 5.717 vs Control: 61.9 ± 2.607), ALT (D*Y: 229.8 ± 6.920 vs Control: 70.7 ± 3.109, D*L: 123.75 ± 6.068 vs Control: 70.7 ± 3.109), and ALP (D*Y: 276.4 ± 18.154 vs Control: 320.6 ± 9.829, D*L: 298.5 ± 12.336 vs Control: 320.6 ± 9.829) in IU/L. The analysis of histological alterations showed hepatic sinusoidal dilation with vein congestion and cell infiltration exclusively in D*Y rats along with other histological changes that are common to both test groups, thereby suggesting more pronounced alterations in D*Y rats. Further, LC–MS/MS based label-free quantitation of proteins from liver tissues revealed 74.75% up-regulated, 25.25% down-regulated in D*Y rats and 51.16% up-regulated, 48.84% down-regulated in D*L experiments. The proteomics-identified proteins majorly belonged to metabolism, apoptosis, stress response and redox homeostasis, and detoxification and antioxidant defence that demonstrated the potential damage of rat liver, more pronounced in D*Y rats. Altogether the results are in favor that the administration of lactobacilli somewhat protected the rat hepatic cells against the diclofenac-induced toxicity. Graphical abstract
- 10 July 2024
- Published by Springer Nature in Biotechnology Letters
- Vol. 46 (5) , 1-20
Proteome profiling, biochemical and histological analysis of diclofenac-induced liver toxicity in Yersinia enterocolitica and Lactobacillus fermentum fed rat model: a comparative analysis
Diclofenac is a hepatotoxic non-steroidal anti-inflammatory drug (NSAID) that affects liver histology and its protein expression levels. Here, we studied the effect of diclofenac on rat liver when co-administrated with either Yersinia enterocolitica strain 8081 serotype O:8 biovar 1B (D*Y) or Lactobacillus fermentum strain 9338 (D*L). Spectroscopic analysis of stool samples showed biotransformation of diclofenac. When compared with each other, D*Y rats lack peaks at 1709 and 1198 cm−1, while D*L rats lack peaks at 1411 cm−1. However, when compared to control, both groups lack peaks at 1379 and 1170 cm−1. Assessment of serum biomarkers of hepatotoxicity indicated significantly altered activities of AST (D*Y: 185.65 ± 8.575 vs Control: 61.9 ± 2.607, D*L: 247.5 ± 5.717 vs Control: 61.9 ± 2.607), ALT (D*Y: 229.8 ± 6.920 vs Control: 70.7 ± 3.109, D*L: 123.75 ± 6.068 vs Control: 70.7 ± 3.109), and ALP (D*Y: 276.4 ± 18.154 vs Control: 320.6 ± 9.829, D*L: 298.5 ± 12.336 vs Control: 320.6 ± 9.829) in IU/L. The analysis of histological alterations showed hepatic sinusoidal dilation with vein congestion and cell infiltration exclusively in D*Y rats along with other histological changes that are common to both test groups, thereby suggesting more pronounced alterations in D*Y rats. Further, LC–MS/MS based label-free quantitation of proteins from liver tissues revealed 74.75% up-regulated, 25.25% down-regulated in D*Y rats and 51.16% up-regulated, 48.84% down-regulated in D*L experiments. The proteomics-identified proteins majorly belonged to metabolism, apoptosis, stress response and redox homeostasis, and detoxification and antioxidant defence that demonstrated the potential damage of rat liver, more pronounced in D*Y rats. Altogether the results are in favor that the administration of lactobacilli somewhat protected the rat hepatic cells against the diclofenac-induced toxicity. Graphical abstract
- 15 June 2024
- Published by Elsevier
- Vol. 141, 495-538
Gut microbial metalloproteins and its role in xenobiotics degradation and ROS scavenging
- 15 June 2024
- Published by Elsevier
- Vol. 141, 495-538
Gut microbial metalloproteins and its role in xenobiotics degradation and ROS scavenging
- 2 April 2024
- Published by Springer Nature
- p. 215-252
Embracing Industry 4.0 Ingredients in Synthetic Biology for the Development of Carbon–Neutral Economy
- 2 April 2024
- Published by Springer Nature
- p. 215-252
Embracing Industry 4.0 Ingredients in Synthetic Biology for the Development of Carbon–Neutral Economy
- Open Access
- 17 January 2024
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 13 (1) , e0089023
Draft genome sequence of Kluyvera ascorbata HAK22 isolated from human feces
The whole genome sequence of rare human pathogen Kluyvera ascorbata strain HAK22 is reported. The K. ascorbata HAK22 was isolated from healthy human from Gurugram, Haryana, India. The draft genome has a length of 4.7 Mbp, with 54.36% GC content and 4,411 proteins, 4,470 genes, and 18 antimicrobial resistance genes.
- 17 January 2024
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 13 (1) , e0089023
Open AccessDraft genome sequence of Kluyvera ascorbata HAK22 isolated from human feces
The whole genome sequence of rare human pathogen Kluyvera ascorbata strain HAK22 is reported. The K. ascorbata HAK22 was isolated from healthy human from Gurugram, Haryana, India. The draft genome has a length of 4.7 Mbp, with 54.36% GC content and 4,411 proteins, 4,470 genes, and 18 antimicrobial resistance genes.